Medication use and disease control of asthmatic patients in Flanders: A cross-sectional community pharmacy study  by Mehuys, E. et al.
ARTICLE IN PRESSRespiratory Medicine (2006) 100, 1407–14140954-6111/$ - s
doi:10.1016/j.r
Correspondi
E-mail addrMedication use and disease control of asthmatic
patients in Flanders: A cross-sectional community
pharmacy study
E. Mehuysa,, L. Van Bortelb, L. Annemansc, J.P. Remona, I. Van
Tongelena, E. Van Gansed, L. Laforestd, G. Chambae, G. BrussellefaPharmaceutical Care Unit Ghent, Faculty of Pharmaceutical Sciences, Ghent University,
Harelbekestraat 72, 9000 Ghent, Belgium
bHeymans Institute of Pharmacology, Faculty of Medicine and Health Sciences, Ghent University,
De Pintelaan 185, 9000 Ghent, Belgium
cDepartment of Public Health, Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan
185, 9000 Ghent, Belgium
dPharmacoepidemiology Unit, University of Lyon, EA 3091 CHU-Lyon, France
eInstitut des Sciences Pharmaceutiques et Biologiques, University of Lyon, 8 Avenue Rockefeller,
69373 Lyon Cedex 08, France
fDepartment of Respiratory Diseases, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
Received 26 April 2005; accepted 12 November 2005KEYWORDS
Asthma;
Pharmacotherapy;
Pharmaceutical
care;
Asthma control;
Disease managementee front matter & 2005
med.2005.11.013
ng author. Tel.: ++32 9
ess: els.mehuys@ugentSummary The aim of this study was to describe medication use and disease
management of asthmatic patients and to evaluate the usefulness of the Asthma
Control Test (ACT) in community pharmacies. In 54 Flemish community pharmacies
166 asthmatic patients were included in the study. At inclusion, the study persons
completed a survey to assess subject characteristics, symptoms and asthma attacks,
and peak expiratory flow (PEF) was measured. Furthermore, the actual level of
asthma control was assessed by ACT, a clinically validated measure of asthma
control. Prescribed medicine data of the patients were 1 year retrospectively
analysed from the prescriptions.
Mean age of the sample was 36.8 year, 23% were smokers. As maintenance
treatment, 63% of the patients used a combination product containing an inhaled
corticosteroid and a long-acting b2-agonist in a single inhaler. According to ACT,
49.1% of the patients were insufficiently controlled. Only 4.9% of the patients had a
maximal ACT score of 25, indicating complete asthma control; 46.0% of the study
population obtained an ACT score between 20 and 24, meaning that their asthma
is well controlled. In contrast, 30.7% of the patients had a score betweenElsevier Ltd. All rights reserved.
2648082; fax.: ++32 9 2228236.
.be (E. Mehuys).
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E. Mehuys et al.140815 and 19, indicating uncontrolled asthma. In all, 18.4% obtained ACT scores of less
than 15, meaning that their asthma was seriously out of control and necessitating
referral to their general practitioner or lung specialist. Importantly, the correlation
between the self-perceived level of asthma control and the objective assessment of
the asthma control level was poor: 82.3% of the patients believed their asthma to be
totally or well controlled, while this was the fact for only 50.9% of the patients. In
conclusion, the ACT appears to be a useful tool to determine rapidly and accurately
the level of asthma control in patients presenting at community pharmacies.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic inflammatory airway di-
sease characterized by widespread, variable and
reversible airflow obstruction associated with
airway hyperresponsiveness, leading to recurrent
episodes of wheezing, breathlessness, chest thight-
ness, and coughing. Throughout the world, asthma
is a major cause of chronic morbidity and eco-
nomic burden. It is estimated that more than 5%
of the world’s population suffers from asthma,
and its prevalence is still increasing. A full
explanation for this increase has not been found,
but it is suggested that it is related with the
increasing urbanization and adoption of western
lifestyles.1
The aim of asthma management is to achieve and
maintain control of the disease.2–4 Asthma manage-
ment guidelines, such as Global Initiative for
Asthma (GINA), have been developed to obtain
optimal asthma control and to provide effective
medical care for asthmatic patients. Despite the
improved treatment options and the existence of
asthma management guidelines, large-scale tele-
phonic surveys such as the Asthma Insights and
Reality (AIR) surveys which were conducted in
America, Europe, Asia-Pacific and Japan, have
shown that control of asthma is suboptimal for
many patients.5 In order to improve asthma
control, asthma management programs are exten-
sively promoted in primary care. Due to their
frequent contact with the patient on prescription
refill, community pharmacists are well placed to
play an important role in the management of
asthmatic patients. However, studies investigating
asthma management in a community pharmacy
setting are rare.
The aim of this pharmacy-based study was to
describe medication use and disease manage-
ment of asthmatic patients and to assess asthma
control via the Asthma Control Test (ACT), a
clinically validated measure of asthma control.6
This work has been presented in part in abstract
form.7Materials and methods
Study design and methods
This asthma study was carried out as a 1-year
retrospective, cross-sectional, multicenter trial
(start of the study: January 2004) describing the
medication use of asthmatic patients. The anti-
asthma medication as well as all other prescri-
ption drugs purchased by each patient, during
the 12 months before inclusion in the study,
was reviewed from the anonymous prescriptions
from the pharmacy files. At inclusion of the
subjects, their actual level of asthma control (by
means of the ACT) and peak expiratory flow (PEF)
was assessed. PEF data are the best of three
measurements and are expressed as the percentage
of the predicted value.8 Furthermore, the study
persons completed a written questionnaire provid-
ing personal information, information on asthma
symptoms and attacks, occurrence of side effects
of the asthma medication, doctor’s visits, use of
alternative medicine and possession of a written
action plan. The same study was conducted
simultaneously in community pharmacies in
France.9
Fifty-four community pharmacies in Flanders
(Belgium) were chosen for the study. These
pharmacies were selected because they act as a
trainee post for the Pharmaceutical Sciences
students of Ghent University. The pharmacy trai-
nees were responsible for the study and performed
the data collection during the study. The pharma-
cies were not payed for participation at the
project.
Asthmatic patients were identified by means of
their medication. In each pharmacy, the first 4
patients purchasing asthma medication in the
pharmacy and fulfilling the following criteria were
included in the study: patients taking prescribed
asthma medication for at least 1 year, having a
smoking history of less than 10 pack-years (to focus
as much as possible on asthma, not on COPD), aged
between 18 and 50 years, being regular visitors of
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Table 1 Patient characteristics.
Age (yr) (SD) 36.8 (10.8)
Sex, % female 56.6%
Age at asthma diagnosis 16.0 (13.3)
Body Mass Index
Men (SD) 25.6 (4.8)
Women (SD) 24.6 (5.6)
Smoking
Non-smokers 77.6%
Current smokers 22.4%
1–9 cigarettes/day 10.9%
10–20 cigarettes/day 8.5%
420 cigarettes/day 3.0%
Medication use and disease control of asthmatic patients in Flanders 1409the pharmacy and willing to participate in the
study. All patients provided written informed
consent before enrollment into the study. The
project was approved by the Ethics Committee of
the Ghent University Hospital. The general practi-
tioner of each patient was informed about the
project by letter.
The severity of a patient’s asthma was classified
in four levels (Intermittent, Mild Persistent, Mod-
erate Persistent and Severe Persistent) based on
the clinical features present—both symptoms dur-
ing the day and nighttime symptoms—as well as the
PEF measurements (Global Initiative for Asthma
(GINA), 1995).
Level of asthma control
At inclusion, the actual asthma control was
assessed by the ACT survey, a clinically validated
measure of asthma control.6 The ACT is a 5-item
questionnaire asking the respondent to consider
the impact of asthma on everyday functioning,
shortness of breath, use of rescue medication,
nocturnal asthma symptoms and the patient’s
rating of asthma control, during the last 4 weeks.
For each question five answer possibilities were
proposed, classified by decreasing level of asthma
control. The ACT score (range, 5–25) for each
subject was determined by summing the responses
to the 5 items, in which a higher score indicated
better asthma control. Patients with an ACT score
of at least 20 points were classified as ‘‘controlled’’
(25 ¼ ‘‘totally controlled’’; 20–24 ¼ ‘‘well con-
trolled’’), while patients with a score of less than
20 points were considered as ‘‘insufficiently con-
trolled’’.Results
Patient characteristics
Of the 224 asthmatic patients meeting the inclusion
criteria, 166 patients (72 men and 94 women)
participated in the study. Thirty-three patients
refused to participate, the main reasons for refusal
were: no time, no interest and violation of privacy.
Twenty-five persons dropped out of the study
because they did not return their questionnaires
to the pharmacy.
The mean age of the patients was 36.8710.8
year (Table 1). The prevalence of current smokers
among these asthmatic patients was high (23%) and
more than half of these smoked at least 10
cigarettes per day (Table 1). The mean age atdiagnosis of asthma was 16.0713.3 years. The
mean PEF of the study population was 78.5721.8%
of the predicted value. The frequency of daily
asthma crises was less than once a week for the
majority of the patients (75.9%), while 17.7% of the
patients reported to have several crises per week.
Noctural asthma symptoms were absent for 64.0%
of the study persons; nocturnal awakening due to
asthma occurred more than twice a month for
20.1% and more than once a week for 12.2%. During
the last 2 weeks, a minority of the study persons
reported to have been hindered by asthma symp-
toms such as wheezing, chest tightness or cough
(Table 2). Using the symptom-based GINA classifi-
cation method of asthma severity (GINA 1995), 30%
of the patients were classified as intermittent, 38%
as mild persistent, 12% as moderate persistent and
20% as severe persistent.Assessment of asthma control by the ACT
According to the ACT, 49.1% of the patients were
insufficiently controlled during the last 4 weeks
showing symptoms of dyspnoea (during day and
night), lifestyle restrictions and regular need of
short-acting bronchodilators (Table 3). The correla-
tion between the self-perceived level of asthma
control and the objective assessment of level of
asthma control—as assessed by the ACT—was poor.
In all, 82.3% of the patients believed their asthma
to be totally or well controlled, while this was the
fact for only 50.9% of the patients. The ACT scores
according to the asthma severity class are shown in
Fig. 1.
The survey also questioned on factors provoking
an asthma-attack. The most cited provoking factor
was a respiratory infection; other frequently
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Table 2 Asthma-attacks and symptoms.
Frequency of daytime asthma crises
p1 /week 75.9%
Several times/week 17.7%
X1 /day 6.4%
Frequency of nocturnal asthma crises
Never 64.0%
X2 /month 20.1%
X1 /week 12.3%
Almost every night 3.6%
Wheezing
Never/very rarely 35.4%
Rarely/sometimes 45.1%
Quite often 8.5%
Almost always/always 11.0%
Chest tightness
Never/very rarely 53.6%
Rarely/sometimes 36.7%
Quite often 4.8%
Almost always/always 4.9%
Cough
Never/very rarely 56.6%
Rarely/sometimes 31.3%
Quite often 6.6%
Almost always/always 5.5%
Table 3 Asthma control level assessed by means
of the Asthma Control Test.
Hinder in daily activities
Never 12.7%
Rarely 30.7%
Sometimes 43.4%
Most of the time 10.2%
All of the time 3.0%
Shortness of breath
Never 37.0%
1–2 times/week 38.3%
3–6 times/week 8.6%
Once a day 5.6%
More than once a day 10.5%
Night wakening
Never 37.0%
Once or twice 36.4%
Once a week 9.3%
2–3 nights/week 9.9%
4 or more nights/week 7.4%
Use of short-acting bronchodilators
Never 29.7%
Once a week or less 26.7%
A few times a week 16.3%
1 or 2 times per day 16.4%
3 or more times per day 10.9%
Patients’ perception of their asthma control
Completely controlled 39.0%
Well controlled 43.3%
Somewhat controlled 11.6%
Poorly controlled 4.9%
Not controlled at all 1.2%
ACT score ¼
25 4.9%
20–24 46.0%
E. Mehuys et al.1410reported factors were physical effort, tobacco,
stress/emotions, air pollution and allergens of
animal and vegetable origin. An increased use of
rescue medication was for the majority of the
patients the most important sign of worsening of
their asthma.15–19 30.7%
o 15 18.4%
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Figure 1 ACT scores according to the asthma severity
class (GINA 1995).Asthma treatment
The majority of the patients consulted a general
practitioner for their asthma on a 1–3 monthly basis
and visited a pneumologist once or twice a year.
Only 6.2% of the patients had been admitted to a
hospital due to asthma during the last 12 months. A
remarkable fact was that quite a large proportion
of the patients (29.3%) had recourse to alternative
medicine, especially homeopathy (22.3%).
As maintenance treatment the majority of the
patients used a combination product containing an
inhaled corticosteroid and a long-acting b2-agonist
in a single inhaler (Seretides or Symbicorts)
(Table 4). Alternatives to these combination pro-
ducts are the separate use of inhalation corticos-
teroids plus a long-acting inhaled b2-agonist or oral
sustained release theophylline. Rescue medication
consisted mainly of rapid-acting inhaled b2-agonists(47.8%) and combination products containing in-
haled anticholinergics and rapid-acting inhaled b2-
agonists (26.4%). More than half of the study
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Table 4 Overview of the anti-asthma medication
use of the study population.
Daily controller medication
Inhaled corticosteroids 40.9%
Long-acting beta-agonists 19.5%
Combination products (Seretides or
Symbicorts)
62.9%
Oral xanthines 18.9%
Leukotriene modifiers 27.0%
Relief medication
Short-acting beta-agonists (SABA) 47.8%
Inhaled short-acting anticholinergics 5.7%
Inhaled short-acting
anticholinergics+SABA
26.4%
Medication use and disease control of asthmatic patients in Flanders 1411persons reported side effects of the asthma
medication: palpitations (24.7%), hoarse voice
(16.9%), fatigue (16.3%), irritated throat (13.3%),
insomnia (10.8%), excitation (10.2%) and headache
(9.0%) were the most reported side effects.
More than half of the patients (53.5%) had used
antibiotics during the last year. Also oral corticos-
teroids (22.6%), muco-regulators (22.6%) and anti-
tussiva (29.6%) were frequently delivered to the
asthmatic patients. Furthermore, 12.4% of the
patients consumed nasal corticosteroids in mono-
therapy, 22.5% antihistaminics in monotherapy and
17.8% combined nasal corticosteroids and antihis-
taminics. More than half of the patients thus had
used antihistaminics or nasal corticosteroids, sug-
gesting co-morbidity of allergic rhinitis.Asthma management instructions and
information
Asthma management not only encompasses the
prescription of anti-asthma medication, but also
patient education, instruction of the proper use of
inhaler devices, and the administration of asthma
action plans. Written asthma action plans inform
patients how to adjust the asthma medication and
how to manage an asthma attack. Interestingly,
only 35% of the patients possessed a detailled
asthma action plan in case of an asthma crisis. The
proportion of patients having an asthma action plan
varied from 22.0% for the patients consulting only a
general practitioner to 41.3% for those visiting only
a pneumologist and 41.7% for those patients visiting
both a general practitioner and a pneumologist.
The questionnaire also asked the patients who
gave them the instruction on how to use the inhaler
devices. Most of them (74.8%) learned it only from
their doctor (general practitioner or pneumolo-gist), 6.7% only from the pharmacist and 16.0% from
both doctor and pharmacist. In 2.5% of the cases,
nobody explained the inhaler technique.
The patients’ need of information about asthma
was also assessed. More than half of the patients
searched for information about asthma themselves.
The patients are primarily informed about their
disease by their doctor. Other sources of informa-
tion were the pharmacist (30.1%), the patient
information sheet (27.7%), press and internet
(22.9%), and radio/television (11.5%). The vast
majority (88.5%) of the study persons felt suffi-
ciently informed about their disease as well as
about their treatment.
Psychological impact of asthma
Asthma had a moderate psychological impact on
the studied population: 42.2% of the patients
declared to consider their disease as a handicap
or an important concern. Furthermore, almost 1
patient on 6 purchased psychotropic drugs. During
the last 2 weeks, almost 15% of the patients
declared to be worried at least ‘quite often’ due
to their asthma. Furthermore, a substantial portion
of the patients felt frustrated (13.5%) at least
‘quite often’ or was afraid not to have their asthma
medication nearby (18.5%). More than a quarter of
the patients was hindered at least ‘quite often’ by
tobacco smoke, while 17% was bothered by dust.Discussion
This study showed that despite the availability of
effective therapies, asthma control is bad or
suboptimal for half of the studied population of
adult patients with persistent asthma, but a
majority is not aware of that. Recently, the Gaining
Optimal Asthma ControL Study (GOAL)—a 1-year
prospective trial comparing salmeterol/fluticasone
propionate with fluticasone propionate monother-
apy in patients with asthma—demonstrated that
guideline-derived asthma control can be achieved
in a majority of the asthmatic patients.10 A possible
drawback of the GOAL study is that it was carried
out as a prospective trial implying careful patient
recruitment, possibly generating a selection bias,
and close follow-up of the patients, resulting in an
unrealistic high compliance of 89%.
Asthma is a variable disorder, due to spontaneous
and therapy-induced variations in severity, thus
regular follow-up of asthmatic patients is required.
In order to improve asthma control asthma manage-
ment programs are extensively promoted in primary
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E. Mehuys et al.1412care. GINA (2002) describes a recommended asthma
management program, consisting of six interrelated
parts: patient education, assessment and monitoring
of asthma severity, avoidance of risk factors,
individual medication plans, individual management
plans for exacerbations and regular follow-up care.2
These guidelines recommend greater participation of
both patients and caregivers in the management of
asthma. Since community pharmacists have recently
expanded their role to giving health care advice for
patients with acute and chronic illness, they can play
an important role in the management of asthmatic
patients. Furthermore, the community pharmacist
has frequent contacts with the patient on account of
their frequent visits to the pharmacy to obtain their
medication. Therapeutic outcomes monitoring is a
model for increasing pharmacists’ role in primary
health care. It is based on the concept of pharma-
ceutical care, a way to optimize drug therapy,
minimize drug-related problems, and improve self-
management and quality of life.11–13
Pharmacists could help in the management of
asthma in several ways. Firstly, the pharmacist
could assess the level of control of the asthmatic
patient. Recently, Nathan et al. (2004) introduced
the ACT, a brief and easy-to-administer procedure
to assess asthma control,6 which has been proven to
detect clinically meaningful changes in asthma
control and FEV1.
14 Our study evaluated the
usefulness of ACT in community pharmacies and
showed that it is a simple and pragmatic method
for quantifying asthma control by both health care
professionals and patients. However, drawback of
the test is that 1 of the 5 items of the ACT questions
the patient for the self-perceived level of control,
which generally results in an overestimation of the
ACT score since many patients overestimate their
level of asthma control. The use of ACT in
community pharmacies could be an efficient tool
to improve asthma control, whereby the pharma-
cist’s advice could depend on the patient’s ACT
score. An ACT score of 20–25 indicates good or
complete asthma control, so for these patients no
specific advice is needed. For patients having an
ACT score of 15–19, indicating uncontrolled asth-
ma, the pharmacist could improve the patient’s
inhalation technique and point the patient at the
importance of adherence to the maintenance
treatment. In case of an ACT score below 15, the
pharmacist should refer the patient immediately to
the GP or lung specialist since these patients are at
risk for severe asthma attacks.
Secondly, it is believed that asthma control can be
optimized if patients regularly monitor their asth-
ma.2 Self-management includes detection of changes
in their condition, making timely adjustments totheir asthma medication and knowing when to seek
medical care. The community pharmacist could help
to improve self-management of asthma by assisting
patients in monitoring their lung function and
symptoms. PEF monitoring is an important clinical
tool providing an objective measure of lung function
and can be used in pharmacy and at home. Active
involvement of community pharmacists in promoting
self-management by PEF measurement and use of
ACT may help to optimize asthma control.
Thirdly, the GINA management program recom-
mends patient education as a means to achieve and
maintain asthma control. Therapeutic failure of
asthma treatment is often the result of poor
adherence to the medication, especially with
respect to the maintenance treatment. Most
important reasons for poor adherence include lack
of immediate benefit from anti-inflammatory ther-
apy, side-effect fears, poor education and resent-
ment about the need for therapy.15 Medication
adherence can be improved by patient education
and self-management programs.3 The pharmacist,
who is trained as an expert in drugs and who is the
last health care professional to come into contact
with the patient, can provide the patient with clear
information on the drug, frequency of administra-
tion, important side effects and correct use of the
inhaler devices. In this survey, 2.5% of the patients
mentioned never have been demonstrated the
inhaler technique. Attention should also be given
to prevention, since asthma exacerbations may be
caused by a variety of triggers including allergens,
pollutants, tobacco smoke, food, and drugs. Pre-
vention aims to reduce the exposure to these
triggers in order to improve the control of asthma
and reduce medication needs.2
Finally, another GINA recommendation is the
possession of a written asthma action plan for the
home management of exacerbations. Recently, a
Cochrane review showed that patients having an
asthma action plan visited less the emergency
department, were less hospitalized and had a
better lung function than patients without an
action plan.16 However, the current study demon-
strated that the spread of action plans under
Flemish asthmatic patients is still insufficient. The
community pharmacist may point the patient at the
usefullness of an action plan.
Some studies have already been performed evalu-
ating the effectiveness of pharmaceutical care in
community pharmacies for patients with asthma.17
Schulz et al.18 studied 178 patients (101 in the
intervention group, 63 in the control group) in
Germany and obtained higher peak flow rates at 6
months in the intervention group, but not at 12
months. However, medication knowledge, inhaler
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intervention group at 12 months. Weinberger et al.19
evaluated 1113 patients (447 in a pharmaceutical care
program, 363 in a PEF rate monitoring control group,
303 in usual care) in the USA. Significantly higher PEF
rates were noticed in the pharmaceutical care group,
compared with the usual care group, but not in the
PEF monitoring group. Stergachis et al.20 studied 330
children in 32 community and clinic pharmacists (14 in
intervention, 18 in usual care) in the USA. Pharma-
cists’ interventions resulted in no significant effect on
asthma outcomes. McLean et al.21 studied 631
patients (191 in enhanced care, 214 in usual care,
226 in a control group) in the USA. Patients in the
pharmaceutical care program had significantly de-
creased symptoms, increased PEF rates, decreased b-
agonist use, improved quality of life scores, increased
knowledge levels, decreased doctor’s visits, emer-
gency department visits and days of sickness. Future
studies should also address the cost-effectiveness of a
pharmaceutical care intervention.
Other significant findings of this study were the high
prevalence of smokers in the sample, and the high
consumption of antihistaminics and/or nasal corticos-
teroids, which is an indication for the important co-
morbidity of allergic rhinitis and asthma.22,23 These
data suggest that 52.7% of the study population
suffers from allergic rhinitis. This percentage may
even be an underestimation of the prevalence of
allergic rhinitis among asthmatics since antihistami-
nics can also be purchased over-the-counter and this
study only registered prescription drugs.Conclusions
Asthma control of Flemish adult asthmatic patients
was suboptimal for half of the studied population.
The Asthma Control Test (ACT) appears to be ideally
suited to determine the level of asthma control in
patients presenting at community pharmacies. Phar-
maceutical care perfomed by pharmacists may
improve clinical and humanistic outcomes in asth-
matic patients. The next step will be to evaluate the
effectiveness and cost-effectiveness of community
pharmacy-based interventions on symptom severity
and health-related quality of life of asthmatic
patients in a controlled prospective study.Acknowledgements
We warmly thank the pharmacists and the patients
who agreed to participate to the study. We also
thank GSK Belgium for the use of ACT.References
1. Masoli M, Fabian D, Holt S, Beasly R. The global burden of
asthma: executive summary of the GINA Dissemination
Committee Report. Allergy 2004;59:469–78.
2. Global Initiative for Asthma (GINA). Global strategy for
asthma management and prevention: NHLBI/WHO Workshop
Report. Bethesda: National Institutes of Health, National
Heart, Lung and Blood Institute; 2002. Publication No. 02-
3659.
3. British Thoracic Society. Scottish Intercollegiate Guidelines
Network. British guideline on the management of asthma.
Thorax 2003;58(Suppl 1):1–94.
4. National Asthma Education and Prevention Program. Guide-
lines for the diagnosis and management of asthma: expert
panel report 2. Betheseda: National Institutes of Health,
National Heart, Lung and Blood Institute; 1997. Publication
No. 97-4051.
5. Rabe KF, Adachi M, Lai CKW, et al. Worldwide severity and
control of asthma in children and adults: the global asthma
insights and reality surveys. J Allergy Clin Immunol
2004;114:40–7.
6. Nathan RA, Sorkness CA, Kosinski M, et al. Development of
the Asthma Control Test: a survey for assessing asthma
control. J Allergy Clin Immunol 2004;113:59–65.
7. Mehuys E, Van Bortel L, Annemans L, et al. Medication use
and disease control of asthma patients in flanders: a
community pharmacy study. Eur Resp Soc Meeting Copenha-
gen A 2005;319.
8. Gregg I, Nunn AJ. Peak expiratory flow in normal subjects.
Brit Med J 1973;3:282–4.
9. Laforest L, Van Ganse E, Devouassoux G, et al. Quality of
asthma care: results from a community pharmacy based
survey. Allergy 2005;60:1505–10.
10. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-
defined asthma control be achieved? The gaining optimal
asthma control study. Am J Respir Crit Care Med
2004;170:836–44.
11. Grainger-Rousseau TJ, Miralles MA, et al. Therapeutic
outcomes monitoring : application of pharmaceutical care
guidelines to community pharmacy. J Am Pharm Assoc
1997;NS37:647–61.
12. Hepler CD, Strand LM. Opportunities and responsibilities in
pharmaceutical care. Am J Hosp Pharm 1990;47:533–43.
13. Hepler CD. TOM Research Group. Asthma TOM-Manual.
Gainesville, FL: University of Florida; 1992.
14. Schatz M, Li JT, Sorkness CA. Responsiveness of the Asthma
Control Test (ACTTM) to changes in specialist’s ratings of
asthma control and FEV1. Am J Respir Crit Care Med
2004;169:A319.
15. Griffith S. A review of the factors associated with patient
compliance and the taking of medicine. Br J Gen Pract
1990;40:114–6.
16. Gibson PG, Powell H, Coughlan J, et al. Self-management
education and regular practitioner review for adults with
asthma. Cochrane Database Syst Rev 2004;1:CD001117.
17. McLean WM, MacKeigan LD. When does pharmaceutical care
impact health outcomes? A comparison of community
pharmacy-based studies if pharmaceutical care for patients
with asthma. Ann Pharmacother 2005;39:625–31.
18. Schulz M, Verheyen F, Muhlig S, et al. Pharmaceutical care
services for asthmatic patients: a controlled intervention
study. J Clin Pharmacol 2001;41:668–76.
19. Weinberger M, Murray MD, Marrero DG, et al. Effectiveness
of pharmacist care for patients with reactive airways
ARTICLE IN PRESS
E. Mehuys et al.1414disease-a randomized controlled trial. JAMA 2002;288:
1594–602.
20. Stergachis A, Gardner JS, Anderson MT, Sullivan SD.
Improving pediatric asthma outcomes in the community
setting: does pharmaceutical care make a difference. J Am
Pharm Assoc 2002;42:743–52.
21. McLean W, Waller R, Gillis J. The BC community pharmacy
study: a study of clinical, economic, and holistic outcomes
influenced by an asthma care protocol provided by speciallytrained community pharmacists in British Columbia. Can
Resp J 2003;10:195–202.
22. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis
and its impact on asthma. J Allergy Clin Immunol
2001;108(5 Suppl):S147–334.
23. Braunstahl GJ. The unified immune system: respiratory
tract-nasobronchial interaction mechanisms in allergic air-
way disease. J Allergy Clin Immunol 2005;115:142–8.
